Loading clinical trials...
Loading clinical trials...
Mycophenolate Mofetil (MMF) ,Carnitine and Phosphodiesterase Type 5 Inhibitor, Three Potential Treatments for Resistant Proteinuria and for Slowing the Deterioration of Diabetic Nephropathy in Patients With Type II Diabetes Mellitus
Conditions
Interventions
Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE
Locations
1
Israel
Nazareth hospital (EMMS)
Nazareth, Israel
Start Date
April 1, 2012
Primary Completion Date
June 1, 2013
Completion Date
August 1, 2013
Last Updated
March 29, 2012
NCT07241390
NCT06926660
NCT06717698
NCT07450820
NCT04592640
NCT06306963
Lead Sponsor
The Nazareth Hospital, Israel
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions